Huber J, Foidart J M, Wuttke W, Merki-Feld G S, The H S, Gerlinger C, Schellschmidt I, Heithecker R
Universität Frauenklinik, Vienna, Austria.
Eur J Contracept Reprod Health Care. 2000 Mar;5(1):25-34. doi: 10.1080/13625180008500375.
To assess the contraceptive reliability, cycle control and tolerability of a new monophasic oral contraceptive containing 30 g ethinylestradiol plus 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany), it was compared with an established oral contraceptive containing 30 g ethinylestradiol plus 150 g desogestrel (Marvelon, NV Organon, Oss, The Netherlands).
A randomized, open-label, 13-cycle study was performed at 80 European centers. Contraceptive reliability, cycle control, blood pressure, body weight, the incidence of adverse events and skin condition were assessed during 13 cycles of oral contraceptive use, and at follow-up. Subjects recorded body weight on three consecutive days pretreatment and weekly thereafter.
Of 2069 women who started the study and received the trial preparations in a ratio of 4:1 (ethinylestradiol/drospirenone, n = 1657; ethinylestradiol/desogestrel, n = 412), 1615 completed the 13 cycles plus follow-up, providing data for over 23,000 evaluable cycles. Eleven pregnancies occurred during treatment, only one of which (in the ethinylestradiol/drospirenone group) could not be ascribed to user failure or interaction with other factors. Both preparations provided effective contraception and cycle control. Pre-existing acne and seborrhea were improved and blood pressure was essentially unchanged. The two treatments differed in their effect on body weight, the difference being statistically significant. In the ethinylestradiol/drospirenone group, there was a distinct decrease over the whole treatment phase, while a subtle and less distinct decrease was documented in the ethinylestradiol/desogestrel group.
The combination of 30 g ethinylestradiol/3 mg drospirenone provides effective oral contraception, excellent cycle control, good tolerability and a level of weight loss that may have a significant beneficial effect on compliance in women with a tendency to weight gain due to water retention.
为评估一种含30μg炔雌醇加3mg屈螺酮的新型单相口服避孕药(优思明,德国先灵公司,柏林)的避孕可靠性、周期控制及耐受性,将其与一种含30μg炔雌醇加150μg去氧孕烯的已上市口服避孕药(妈富隆,荷兰欧加农公司,奥斯)进行比较。
在80个欧洲中心开展了一项随机、开放标签的13周期研究。在口服避孕药使用的13个周期及随访期间,评估避孕可靠性、周期控制、血压、体重、不良事件发生率及皮肤状况。受试者在治疗前连续3天记录体重,此后每周记录一次。
2069名开始研究并按4:1比例接受试验制剂的女性(炔雌醇/屈螺酮组,n = 1657;炔雌醇/去氧孕烯组,n = 412)中,1615名完成了13个周期加随访,提供了超过23000个可评估周期的数据。治疗期间发生了11次妊娠,其中只有1次(在炔雌醇/屈螺酮组)不能归因于使用者失误或与其他因素的相互作用。两种制剂均提供了有效的避孕和周期控制。原有痤疮和脂溢性皮炎得到改善,血压基本未变。两种治疗对体重的影响不同,差异具有统计学意义。在炔雌醇/屈螺酮组,整个治疗阶段体重有明显下降,而炔雌醇/去氧孕烯组体重有轻微且不太明显的下降。
30μg炔雌醇/3mg屈螺酮组合提供了有效的口服避孕、出色的周期控制、良好的耐受性以及一定程度的体重减轻,这可能对因水潴留而有体重增加倾向的女性的依从性产生显著有益影响。